Wedbush Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $70

Wedbush analyst Martin Fan initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $70.